Drug or treatment

Telisotuzumab clinical trials

• 14Clinical trials
• 35Countries

Newest trials

All recruiting trials (14)

• Telisotuzumab Adizutecan with Gemcitabine and Nab-Paclitaxel in Pancreatobiliary Cancers

  This study tests whether adding telisotuzumab adizutecan to standard chemotherapy can help adults with pancreatobiliary cancers see a benefit.

  Recruiting at 7 sites Phase 2 AbbVie · Hattiesburg, Mississippi and 6 other locations · NCT07769502

• Telisotuzumab Adizutecan with Pembrolizumab as first-line treatment for recurrent or metastatic head and neck cancer

  This study tests a combination treatment to see if it helps people with newly diagnosed recurrent or metastatic head and neck squamous cell carcinoma who express the c-Met protein.

  Recruiting at 5 sites Phase 2 AbbVie · Duarte, California and 4 other locations · NCT07744126

• Telisotuzumab Adizutecan with Bevacizumab vs LONSURF with Bevacizumab in refractory metastatic colorectal cancer

  This study tests whether adding telisotuzumab adizutecan to bevacizumab helps adults with refractory metastatic colorectal cancer more than the standard care of LONSURF plus bevacizumab.

  Recruiting at 88 sites Phase 3 AbbVie · Goodyear, Arizona and 87 other locations · NCT07525206

• Telisotuzumab adizutecan with FOLFOX versus standard care in first-line metastatic pancreatic cancer

  This study tests whether adding telisotuzumab adizutecan to FOLFOX helps adults with unresectable, metastatic pancreatic cancer compare to standard treatment.

  Recruiting at 22 sites Phase 2/3 AbbVie · New Haven, Connecticut and 21 other locations · NCT07490301

• Telisotuzumab vedotin combined with osimertinib for progressive, incurable non-small cell lung cancer

  This trial tests whether adding the antibody-drug telisotuzumab vedotin to ongoing osimertinib can shrink tumors or slow growth in adults with progressive, incurable non-small cell lung cancer who have EGFR mutations.

  Recruiting Phase 2 Jonsson Comprehensive Cancer Center · Los Angeles, California · NCT07323641

• Telisotuzumab adizutecan for advanced solid tumors with MET amplification (ages 12+)

  This trial will try an IV drug called telisotuzumab adizutecan in people 12 years and older whose advanced solid tumors have MET amplification to see if it can control tumor activity and what side effects occur.

  Recruiting at 38 sites Phase 2 AbbVie · Beverly Hills, California and 37 other locations · NCT07196644

• IV telisotuzumab adizutecan versus standard treatment for adults with advanced EGFR‑mutated non‑squamous NSCLC

  This trial tests whether IV telisotuzumab adizutecan works better than standard treatment for adults with advanced non‑squamous non‑small cell lung cancer that has EGFR exon 19 deletion or L858R mutation.

  Recruiting at 117 sites Phase 2/3 AbbVie · Springdale, Arkansas and 116 other locations · NCT07155187

• Comparing IV telisotuzumab adizutecan versus standard care for colorectal cancer patients who are ctDNA-positive with no visible disease

  This tests whether an IV drug, telisotuzumab adizutecan, or standard care can help adults with colorectal cancer who are ctDNA-positive after adjuvant therapy but have no visible disease on scans.

  Recruiting at 47 sites Phase 2 AbbVie · Huntsville, Alabama and 47 other locations · NCT07023289

• Telisotuzumab adizutecan plus osimertinib for first-line treatment of advanced EGFR-mutated non-squamous NSCLC

  This test adds the investigational drug telisotuzumab adizutecan to osimertinib (or to osimertinib plus chemotherapy) to see if it helps adults with newly diagnosed advanced EGFR-mutated non-squamous non-small cell lung cancer and to check side effects.

  Recruiting at 63 sites Phase 2/3 AbbVie · Chandler, Arizona and 64 other locations · NCT07005102

• Evaluating a new treatment for metastatic colorectal cancer

  This study is testing a new drug combined with standard chemotherapy to see if it helps adults with metastatic colorectal cancer feel better and improve their condition.

  Recruiting at 82 sites Phase 2 AbbVie · Duarte, California and 81 other locations · NCT06820463

• Evaluating a new treatment for advanced non-squamous lung cancer

  This study is testing a new combination of medications for adults with advanced lung cancer who haven't had treatment before, to see if it is safe and effective.

  Recruiting at 123 sites Phase 1/2 AbbVie · Phoenix, Arizona and 126 other locations · NCT06772623

• Assessing the safety of telisotuzumab vedotin in adults with non-small cell lung cancer

  This study is testing a new drug called telisotuzumab vedotin to see if it is safe for adults with non-small cell lung cancer that has already been treated.

  Recruiting at 80 sites Phase 2 AbbVie · Chandler, Arizona and 82 other locations · NCT06568939

• Assessing the safety and effects of Azirkitug in cancer patients

  This study is testing a new cancer drug called Azirkitug to see how safe it is and how well it works for adults with certain types of lung and head and neck cancers.

  Recruiting at 47 sites Phase 1 AbbVie · Duarte, California and 47 other locations · NCT05005403

• Comparing Telisotuzumab Vedotin and Docetaxel for Non-Small Cell Lung Cancer

  This study is testing whether a new drug called telisotuzumab vedotin is better than the standard treatment docetaxel for adults with a specific type of lung cancer that has already been treated.

  Recruiting at 263 sites Phase 3 AbbVie · Birmingham, Alabama and 316 other locations · NCT04928846

Quick answers

How many clinical trials of Telisotuzumab are recruiting right now?

14, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 35 countries. The most sites are in United States (14 trials), Japan (13 trials), Taiwan (11 trials), Israel (9 trials), South Korea (8 trials). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 2: 7, Phase 2/3: 3, Phase 3: 2, Phase 1: 1. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →